Center for Biologics Evaluation and Research Report of Scientific and Medical Literature and Information on Non-Standardized Allergenic Extracts in the Diagnosis and Treatment of Allergic Disease; Extension of Comment Period
Health and Human Services Department, Food and Drug Administration
What is this?
This is a regulatory record from Health and Human Services Department, Food and Drug Administration — a rule, proposed rule, or notice. Regulations carry the force of law once final, and often invite public comment before that point.
Why does it matter?
Regulations are usually what actually binds you, more than statutes are. This is where an agency states the requirement, the effective date, and whether there is still a window to respond.
Key Details
- Posted Date
- Response Deadline
- NAICS Code
- 621999
- Source
- Federal Register
- Contract Type
- regulation
Description
The Food and Drug Administration (FDA) is extending to April 25, 2012, the comment period for the notice on its report of scientific and medical literature and information concerning the use of non- standardized allergenic extracts in the diagnosis and treatment of allergic disease that appeared in the Federal Register of September 26, 2011 (76 FR 59407). In the notice, FDA requested comments from public and private stakeholders on the report it provided in a data file entitled "Center for Biologics Evaluation and Research Report of Scientific and Medical Literature and Information on Non-Standardized Allergenic Extracts in the Diagnosis and Treatment of Allergic Disease." The Agency is taking this action in response to input it received from the Allergenic Products Advisory Committee (APAC) at a meeting held on October 25, 2011, to allow interested persons additional time to submit comments.
Key Dates
Frequently Asked Questions
Does this regulation apply to me?+
Follow This Regulation
Follow this regulation in Bureauify to see changes as they are published.
Intelligence
- Win probability analysis
- Competitive landscape
- Incumbent analysis
- Price-to-win estimate
- Similar awards history